CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
Multiple myeloma (MM) is an incurable malignancy of the B-cell lineage. Remarkable progress has been made in the treatment of MM with anti-CD38 monoclonal antibodies such as daratumumab and isatuximab, which can kill MM cells by inducing complement-dependent cytotoxicity (CDC). We showed that the CDC efficacy of daratumumab and isatuximab is limited by membrane complement inhibitors, including CD46 and CD59, which are upregulated in MM cells. We recently developed a small recombinant protein, Ad35K++, which is capable of transiently removing CD46 from the cell surface. We also produced a peptide inhibitor of CD59 (rILYd4). In this study, we tested Ad35K++ and rILYd4 in combination with daratumumab and isatuximab in MM cells as well as in cells from two other B-cell malignancies. We showed that Ad35K++ and rILYd4 increased CDC triggered by daratumumab and isatuximab. The combination of both inhibitors had an additive effect in vitro in primary MM cells as well as in vivo in a mouse xenograft model of MM. Daratumumab and isatuximab treatment of MM lines (without Ad35K++ or rILYd4) resulted in the upregulation of CD46/CD59 and/or survival of CD46high/CD59high MM cells that escaped the second round of daratumumab and isatuximab treatment. The escape in the second treatment cycle was prevented by the pretreatment of cells with Ad35K++. Overall, our data demonstrate that Ad35K++ and rILYd4 are efficient co-therapeutics of daratumumab and isatuximab, specifically in multi-cycle treatment regimens, and could be used to improve treatment of multiple myeloma.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
Cancer biology & therapy - 25(2024), 1 vom: 31. März, Seite 2314322 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Hongjie [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 19.02.2024 Date Revised 11.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/15384047.2024.2314322 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368514358 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368514358 | ||
003 | DE-627 | ||
005 | 20240312233839.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240216s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/15384047.2024.2314322 |2 doi | |
028 | 5 | 2 | |a pubmed24n1324.xml |
035 | |a (DE-627)NLM368514358 | ||
035 | |a (NLM)38361357 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Hongjie |e verfasserin |4 aut | |
245 | 1 | 0 | |a CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.02.2024 | ||
500 | |a Date Revised 11.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Multiple myeloma (MM) is an incurable malignancy of the B-cell lineage. Remarkable progress has been made in the treatment of MM with anti-CD38 monoclonal antibodies such as daratumumab and isatuximab, which can kill MM cells by inducing complement-dependent cytotoxicity (CDC). We showed that the CDC efficacy of daratumumab and isatuximab is limited by membrane complement inhibitors, including CD46 and CD59, which are upregulated in MM cells. We recently developed a small recombinant protein, Ad35K++, which is capable of transiently removing CD46 from the cell surface. We also produced a peptide inhibitor of CD59 (rILYd4). In this study, we tested Ad35K++ and rILYd4 in combination with daratumumab and isatuximab in MM cells as well as in cells from two other B-cell malignancies. We showed that Ad35K++ and rILYd4 increased CDC triggered by daratumumab and isatuximab. The combination of both inhibitors had an additive effect in vitro in primary MM cells as well as in vivo in a mouse xenograft model of MM. Daratumumab and isatuximab treatment of MM lines (without Ad35K++ or rILYd4) resulted in the upregulation of CD46/CD59 and/or survival of CD46high/CD59high MM cells that escaped the second round of daratumumab and isatuximab treatment. The escape in the second treatment cycle was prevented by the pretreatment of cells with Ad35K++. Overall, our data demonstrate that Ad35K++ and rILYd4 are efficient co-therapeutics of daratumumab and isatuximab, specifically in multi-cycle treatment regimens, and could be used to improve treatment of multiple myeloma | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Multiple myeloma | |
650 | 4 | |a complement dependent cytotoxicity | |
650 | 4 | |a daratumumab | |
650 | 4 | |a isatuximab | |
650 | 4 | |a resistance | |
650 | 7 | |a daratumumab |2 NLM | |
650 | 7 | |a 4Z63YK6E0E |2 NLM | |
650 | 7 | |a isatuximab |2 NLM | |
650 | 7 | |a R30772KCU0 |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a ADP-ribosyl Cyclase 1 |2 NLM | |
650 | 7 | |a EC 3.2.2.6 |2 NLM | |
650 | 7 | |a CD59 protein, human |2 NLM | |
650 | 7 | |a 101754-01-2 |2 NLM | |
650 | 7 | |a CD59 Antigens |2 NLM | |
650 | 7 | |a CD46 protein, human |2 NLM | |
650 | 7 | |a Membrane Cofactor Protein |2 NLM | |
700 | 1 | |a Koob, Theo |e verfasserin |4 aut | |
700 | 1 | |a Fromm, Jonathan R |e verfasserin |4 aut | |
700 | 1 | |a Gopal, Ajay |e verfasserin |4 aut | |
700 | 1 | |a Carter, Darrick |e verfasserin |4 aut | |
700 | 1 | |a Lieber, André |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer biology & therapy |d 2002 |g 25(2024), 1 vom: 31. März, Seite 2314322 |w (DE-627)NLM12031438X |x 1555-8576 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:31 |g month:03 |g pages:2314322 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/15384047.2024.2314322 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 25 |j 2024 |e 1 |b 31 |c 03 |h 2314322 |